Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Liquid Biopsy Approaches to Capture Tumour Evolution and Clinical Outcomes During Cancer Immunotherapy

Review Sample Work

Cancer immunotherapy has made a significant impact on the treatment of this disease; however, patient outcomes differ due to the evolving nature of cancer under treatment. Conventional biopsies provide limited data and do not reflect these changes in real time. Liquid biopsy, which includes the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other blood-based biomarkers, is a non-invasive method that can monitor tumor evolution. This case report highlights the value of liquid biopsy in assessing tumor dynamics, monitoring treatment response, and detecting emerging resistance during cancer immunotherapy. Therefore, liquid biopsy represents a promising tool for improving patient monitoring and clinical decision-making in oncology practice.

Summarising an immuno-oncology review in eight focused sections

Unlike most case report samples, this document does not follow a single patient. It is a condensed, review-style article on how circulating tumour DNA (ctDNA) can be used during cancer immunotherapy, built from a published review in an immunotherapy journal and reproducing three of its figures with attribution. It suits oncologists, translational researchers and medical affairs teams who need an accurate, readable overview of a fast-moving evidence base, and it shows how a long technical review can be reorganised around clinical questions.

After an unstructured abstract and an introduction, the body is divided into six themed sections: biology and detection of ctDNA; tracking tumour evolution; ctDNA-based biomarkers for patient selection; minimal residual disease (MRD) and adjuvant immunotherapy; monitoring response and progression; and ctDNA-guided trials and future perspectives. A short conclusion closes the piece.

What circulating tumour DNA reveals during checkpoint blockade

The introduction frames the clinical problem. Immune checkpoint inhibitors targeting PD-1, PD-L1 and CTLA-4 have extended survival in several solid tumours, yet only a proportion of patients benefit, and reliable biomarkers are needed to select patients and judge response. Tissue biopsy remains the reference method for biomarker testing, but it is invasive, captures a single site at a single time and cannot easily follow a tumour as it changes under treatment.

ctDNA is the fraction of cell-free DNA released by tumour cells through apoptosis, necrosis and active secretion. The sample explains that its quantity in blood tends to reflect tumour size and stage, and that techniques such as droplet digital PCR, targeted next-generation sequencing and whole-genome sequencing can detect point mutations, copy number changes, rearrangements, methylation patterns and fragmentation profiles. It distinguishes tumour-informed assays, which track mutations already identified in a patient's tumour and achieve higher sensitivity, from tumour-agnostic assays that do not require prior tissue sequencing.

The clinical thread from patient selection to residual disease

The body of the sample follows the patient pathway rather than the technology, which makes it easier for clinicians to read:

  • Tumour evolution. Longitudinal ctDNA analysis can show changes in clonal structure, reveal emerging resistance mutations and, combined with T-cell receptor sequencing, describe interactions between tumour and immune system.
  • Patient selection. Blood tumour mutational burden (bTMB) is presented as a biomarker that may reflect heterogeneity across metastatic sites, with the POPLAR, OAK and MYSTIC trials cited as linking it to outcomes after checkpoint inhibition, alongside caveats about assay and threshold differences. Blood-based microsatellite instability is described as an option when tissue is insufficient.
  • MRD and adjuvant therapy. Post-surgical ctDNA is associated with high recurrence risk; the sample cites CheckMate-816 (ctDNA clearance and pathological complete response), IMvigor010 (adjuvant atezolizumab in ctDNA-positive patients) and the DYNAMIC trial (avoiding unnecessary treatment).
  • Response monitoring. Falling ctDNA is associated with benefit and rising levels with resistance, sometimes ahead of imaging, and ctDNA may help separate pseudo-progression from true progression.
  • Future trials. MERMAID-1, MERMAID-2, TOMBOLA, PERSEVERE and ATLAS are listed as studies testing ctDNA-guided intervention.

The three figures support this thread: an overview of detection and analysis approaches, a timeline mapping ctDNA uses from early localised to refractory disease, and a circular diagram of current and emerging cell-free DNA "hallmarks" such as fragmentomics and epigenomics.

Reproducing published figures with proper attribution

Each figure in the sample is labelled "Adopted from" the source review, with a full citation and DOI in the legend. This is the minimum expected when reusing published images, and authors preparing a similar document should also check the source's licence: open-access articles under Creative Commons licences generally permit reuse with attribution, while other material may need permission from the publisher. Journals increasingly ask authors to confirm figure permissions at submission.

For a review-format manuscript, the reporting expectations also differ from those for a case report. Narrative reviews are not governed by a single checklist in the way systematic reviews follow PRISMA, but editors still expect a clear scope, representative and current citations, and a balanced account of limitations. The sample's treatment of bTMB, where it notes unresolved issues with testing methods and cut-offs, is an example of that balance.

When a condensed evidence summary serves readers better than a case

A document of this kind is useful when the goal is to orient readers to a body of evidence rather than to report a new observation: briefing a multidisciplinary team, preparing an educational article or framing the background to a grant or protocol. Writers adapting it should organise sections around decisions clinicians actually face, name the trials that support each claim, and keep speculative material, such as the sample's remarks on epigenetic markers and artificial intelligence, clearly separated in a future-perspectives section.

Pubrica's literature review and gap analysis service supports this kind of evidence synthesis, while clinical literature reviews for evidence-based medicine focus on summaries intended to inform practice. Where a review needs a visual overview, a graphical abstract can present the ctDNA pathway in a single image. This page is a writing sample and does not constitute guidance on cancer testing or treatment.

Questions about this sample

Does this sample describe an individual patient?

No. Although it appears among the case report samples, the document is a review-style summary of a published article on liquid biopsy in cancer immunotherapy. It synthesises evidence on ctDNA detection, patient selection, residual disease and response monitoring rather than reporting a single patient's history.

What is the difference between tumour-informed and tumour-agnostic ctDNA assays?

As the sample explains, tumour-informed assays track mutations already identified by sequencing a patient's tumour tissue, which gives higher sensitivity. Tumour-agnostic assays look for cancer-associated changes without prior knowledge of the tumour's mutations. Both provide molecular data, but they suit different clinical situations and tissue availability.

Which clinical trials does the sample cite on minimal residual disease?

It cites CheckMate-816, which linked ctDNA clearance with pathological complete response; IMvigor010, in which patients with post-surgical ctDNA appeared to benefit from adjuvant atezolizumab; and the DYNAMIC trial, which showed that ctDNA testing can help avoid unnecessary adjuvant treatment. Together they illustrate both risk stratification and treatment de-escalation.

How can ctDNA help with pseudo-progression?

Pseudo-progression occurs when tumours appear to enlarge on imaging because of immune cell infiltration before shrinking. The sample notes that falling or absent ctDNA can indicate genuine response in this situation, helping clinicians avoid stopping an effective immunotherapy on the basis of misleading radiological findings.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.